Write the drug substance manufacturing section

How should CTD 3.2.S.2 describe drug substance manufacturing?

Connect the actual sites and process sequence with material controls, critical steps, relevant validation or evaluation, and development history. Show which process version produced the supporting material. The narrative, flow diagram and evidence should describe the same manufacturing proposal, including transfers, storage and significant changes.

Before you begin

Chemical and biotech substance manufacturing narratives under M4Q(R1); scientific evidence and validation expectations remain product- and process-specific.

What you will prepare: A process narrative and control map traceable to the proposed manufacturing process and executed development evidence.

S.2.1–S.2.2: follow the process across real sites

For S.2.1, obtain the controlled site roster and state each manufacturer's name, address and responsibility, including contractors and testing sites. Distinguish legal entity from physical facility; a headquarters address cannot identify an unlisted manufacturing operation.

For S.2.2, reconcile a process flow diagram with a sequential narrative at the proposed scale. Chemical routes need the relevant materials, transformations, operating conditions, intermediates and controls; explain alternate routes and reprocessing rather than hiding them in a footnote. For biotech manufacture, follow the cell-bank vial through culture, harvest, purification/modification, filling, storage and transport. Explain batch definition, pooling and transfers. A reader should locate every material entry and control point in both the drawing and narrative. Missing ranges go back to the process owner; do not fill them from an example dossier.

S.2.3–S.2.4: explain materials and critical decisions

In S.2.3, map each starting/raw material, reagent, solvent and other relevant input to the step where it is used and the quality control that supports its intended use. For biological materials, obtain origin and safety records; for cell substrates, include the applicable source/history, construct and cell-bank control information. Cross-reference the detailed adventitious-agent assessment in A.2.

In S.2.4, take each critical step identified in S.2.2 and state its test or control, criterion, evidence supporting the choice, and treatment of isolated intermediates. For biotech intermediate storage, connect the proposed conditions to stability evidence. Do not call a step noncritical merely because its limit is missing. Record that gap, obtain the risk/scientific assessment, and reconcile the process diagram after resolution.

S.2.5–S.2.6: distinguish demonstrated capability from process history

Use S.2.5 for the applicable validation/evaluation plans, executed results, interpretation and conclusions. Identify what process version and scale the work supports. M4Q specifically addresses aseptic processing/sterilization and provides additional biotech process-evaluation detail. Route viral removal/inactivation study evidence to A.2 with clear references; use current Q5A(R2) when its product scope applies.

Use S.2.6 to explain significant manufacturing or site changes during development, why they occurred and how their quality impact was assessed. Link nonclinical, clinical, stability and commercial-representative batches to their process versions. For biotech changes, present the comparative evidence and its scientific interpretation; do not equate passing release tests with a complete comparability conclusion. If the bridge is missing, identify the affected studies and assign the assessment before claiming representativeness.

Worked review: a hold time changed between evidence and narrative

Fictional exercise: S.2.2 proposes an overnight intermediate hold, but S.2.4 and the supporting evaluation cover only a shorter hold. The discrepancy is a scope problem, not a typographical choice.

Compare the proposed process to the executed study conditions, obtain the technical owner's assessment, and either support the proposed hold or revise the proposal through change control. Review downstream impurity, stability and batch-representativeness claims. Record the resolved evidence link in S.2.5/S.2.6 as appropriate. Never invent a time limit to make the three sections agree.

Create a process-to-control crosswalk

Review the process horizontally before reviewing each S.2 subsection in isolation. Use the process diagram as the row order for this editorial crosswalk.

“Required working context” describes what the author needs for the comparison; it is not a universal mandated submission table. The technical owner determines the relevant process details and scientific conclusions.

Review exercise: the flow diagram shows purification at site A and final storage at site B, but only A is listed. Identify the operation and responsibility at B, then inspect transfer conditions and the evidence supporting the receiving process. Adding an address without evaluating the transfer would repair only the directory.

Keep development history connected to the process actually proposed. A historical batch can support a useful conclusion without representing every later process condition. Carry that distinction into characterization, substance stability and any adventitious-agent assessment.

Frequently asked questions

Sources and revisions

Requirements, source recommendations and editorial preparation advice have different roles. Review the scope and revision of the source you use.

Related guides